All HEI'sAthlone Institute of TechnologyCork Institute of TechnologyDublin City UniversityDublin Institute of TechnologyMaynooth UniversityNational University of Ireland, GalwayRoyal College of SurgeonsTeagascTrinity College DublinUniversity College CorkUniversity College DublinUniversity of LimerickWaterford Institute of Technology All SectorsFuture Networks and Communications, IoT Data Analytics, Management, Security, Privacy, Robotics and Artificial Intelligence (incl. Machine Learning)Digital Platforms, Content and Applications, Augmented & Virtual RealityConnected Health Medical DevicesDiagnosticsTherapeutics Food for HealthSmart & Sustainable Food Production and Processing Decarbonising the Energy SystemSustainable LivingAdvanced & Smart ManufacturingManufacturing & Novel MaterialsInnovation in Services and Business ProcessingSectorsResearch Theme Sub SectorsRALA/FKBPL: TACKLING OBESITY WITH A NEW NANOMEDICINEObesity costs the UK economy nearly £47 billion per year. 40–70% of inter-individual variability in BMI attributable to genetic factors. Although treatment strategies are available, the side effects associated with their... pdf 1.1MBCDaaS—Clinical Data as a Service The Clinical Data as a Service Platform (CDaaS) brings to GPs, surgeons and third parties, synthetized information of PoC diagnosis data, specifically in this case for the detection of acute infection with the identif... pdf 183.4KBSensCuff - A Non-Invasive Vascular Monitoring and Diagnostics Technology Senscuff provides a means with which to non-invasively monitor a user’s vascular health using standard blood pressure cuff technology and acoustic signal analysis. pdf 347.4KBOptimal power allocation and sharing algorithm - Licensing Opportunity from University College Cork 2019Optimal power allocation and sharing algorithm for maximizing efficient operation of a parallel multi-unit power conversion systempdf 138KBBreast Cancer Biomarkers as a Clinical Management Tool for RCSI June 2019The global market for ER-positive breast cancer is estimated to be 2.86 billion. Despite availability of effective treatments, survival rates are low in Stage IV as compared to other stages. ADAM22 is a novel therapeutic... pdf 437.5KB 123456789101112131415161718192021222324 Last Print Bookmark Top